Goodwin ECM team, led by Ariel White-Tsimikalis, works across a range of sectors with a focus on tech, life sciences, and private equity-backed companies. The group advises on IPOs, dual-track exits, and take-private transactions, with notable experience guiding UK-headquartered businesses through listings on the Main Market, AIM, and US exchanges.
Legal 500 Editorial commentary
Key clients
- Stifel Nicolaus Europe Ltd
- Panmure Liberum Limited
- WG Partners LLP
- Morgan Stanley & Co, Inc.
- Centessa Pharmaceuticals plc
- Orchard Therapeutics plc
- tinyBuild, Inc
- ZQ Capital Limited
Work highlights
Advised Panmure Liberum and and WG Partners as joint bookrunners on AIM-quoted Scancell Holdings plc’s £10.3 million placing and subscription.
Advised Stifel as sole bookrunner on a placing on AIM launched on 12 March 2024 by Renalytix plc (which is also dual listed on Nasdaq), raising gross proceeds of approximately US$12 million.
Advised Morgan Stanley & Co. LLC as financial advisor to Royalty Pharma in its agreement to acquire its external manager, RP Management, LLC.
Practice head
Ariel White-Tsimikalis